(R)-4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylimidazolidin-2-one | 345580-16-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (R)-4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylimidazolidin-2-one
• 英文别名: (4R)-4-[[3,5-bis(trifluoromethyl)phenyl]methoxymethyl]-4-phenylimidazolidin-2-one
• CAS: 345580-16-7
• 化学式: C₁₉H₁₆F₆N₂O₂
• 分子量: 418.339
• InChiKey: PKXHFVKACNEDII-QGZVFWFLSA-N

物化性质

• 沸点：
  470.7±45.0 °C(Predicted)
• 密度：
  1.342±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (R)-4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylimidazolidin-2-one 、 碘甲烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (R)-4-(3,5-Bis-trifluoromethyl-benzyloxymethyl)-1-methyl-4-phenyl-imidazolidin-2-one 、 (R)-5-(3,5-Bis-trifluoromethyl-benzyloxymethyl)-1-methyl-5-phenyl-imidazolidin-2-one
  参考文献：
  名称：

  Cyclic urea derivatives as potent NK1 selective antagonists

  摘要：

  A series of novel five- and six-membered ring urea derivatives have been described as potent and selective NK1 receptor antagonists. Several compounds in this series exhibited good oral activity and brain penetration. Syntheses of these compounds are also described herein. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.111
• 作为产物：
  描述：

  2-(3,5-bis(trifluoromethyl)benzyloxy)-1-phenylethanone 在 lithium aluminium tetrahydride 、 氨 、 zinc(II) iodide 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 为溶剂， 反应 39.0h， 生成 (R)-4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylimidazolidin-2-one
  参考文献：
  名称：

  Cyclic urea derivatives as potent NK1 selective antagonists

  摘要：

  A series of novel five- and six-membered ring urea derivatives have been described as potent and selective NK1 receptor antagonists. Several compounds in this series exhibited good oral activity and brain penetration. Syntheses of these compounds are also described herein. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.111

文献信息

• TREATMENT OF CORNEAL NEOVASCULARIZATION
  申请人：IRBM SCIENCE PARK S.p.A.

  公开号：US20180021327A1

  公开（公告）日：2018-01-25

  There is provided inter alia a compound which is an NK-1 receptor antagonist for use in the treatment or prevention of CNV. There is also provided a compound which is an NK-1 antagonist for use in the treatment of chemical burns of the eye particularly alkali burns of the eye. There is also provided a pharmaceutical composition for topical administration to the eye comprising an NK-1 antagonist and an antibiotic agent.
• NK-1 ANTAGONISTS FOR USE IN THE TREATMENT OF OCULAR PAIN
  申请人：OSPEDALE SAN RAFFAELE S.R.L.

  公开号：US20210015834A1

  公开（公告）日：2021-01-21

  The invention relates to compounds, in particular NK-1 antagonists, for use in the treatment of ocular sensitivity and/or ocular pain.
• US9782397B2
  申请人：——

  公开号：US9782397B2

  公开（公告）日：2017-10-10
• Cyclic urea derivatives as potent NK1 selective antagonists
  作者：Ho-Jane Shue、Xiao Chen、Neng-Yang Shih、David J. Blythin、Sunil Paliwal、Ling Lin、Danlin Gu、John H. Schwerdt、Sapna Shah、Gregory A. Reichard、John J. Piwinski、Ruth A. Duffy、Jean E. Lachowicz、Vicki L. Coffin、Fei Liu、Amin A. Nomeir、Cynthia A. Morgan、Geoffrey B. Varty

  DOI：10.1016/j.bmcl.2005.05.111

  日期：2005.9

  A series of novel five- and six-membered ring urea derivatives have been described as potent and selective NK1 receptor antagonists. Several compounds in this series exhibited good oral activity and brain penetration. Syntheses of these compounds are also described herein. (c) 2005 Elsevier Ltd. All rights reserved.